BioNews (120610)
Courtesy of GEN News
Genzyme to Appoint Two Icahn Nominees to Its Board
Decision is part of settlement for proxy battle initiated by the billionaire activist investor last year.
Study Finds Increased Numbers of Gene-Disrupting CNVs in Autism
Collaborators at the University of Oxford aim to carry out pilot genetic testing trial.
Celera Gets CE Mark for KIF6 Genetic Test for Coronary Heart Disease Risk
The real-time PCR assay is also reported to help predict response to statin therapy.
The Status of U.S. and European Government Funding for Synthetic Biology
The U.S. has invested over two and a half times more than the EU and three European countries.
Forest Laboratories Pays TransTech Pharma $50M Up Front in Diabetes Deal
Agreement covers liver-selective glucokinase activators and is valued at up to $1.105 billion.
Myriad Puts Noncancer Pipeline on Hold and Cuts Workforce
Firm aims to partner all development programs including suspended clinical-stage HIV candidate.
Spanish Plasma Proteins Group Grifols Acquires Talecris for $3.4B
Firms claim merger will enhance global plasma proteins business and provide new pipeline.
Abraxis Reports Phase III Success with Abraxane in First-Line NSCLC
Nab-paclitaxel in combination with carboplatin enhanced ORR by 31%.
Life Technologies and Cancer Centers Form Whole-Genome Sequencing Alliance
Initiative aims to evaluate whether sequencing can help improve treatment decisions for individuals.
Illumina Cuts Price for Individual Genome Sequencing Service by More than Half
Cost for a single person is down to $19,500 from $48,000.
